Everolimus (Afinitor) is not recommended for use within NHS Scotland for the treatment of hormone receptor-positive, human epidermal growth factor type 2 (HER2)/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor. The addition of everolimus to exemestane treatment significantly increased progression free survival compared with exemestane alone in postmenopausal women with disease progression following a non-steroidal aromatase inhibitor. Novartis did not present a sufficiently robust economic analysis to gain acceptance by SMC. Novartis has indicated their intention to lodge a resubmission.  For more details, go to http://www.scottishmedicines.org.uk/SMC_Advice/Advice/872_13_everolimus_Afinitor/everolimus_Afinitor